Smalley KS - Search Results

1

Improving patient outcomes to targeted therapies in melanoma.

Eroglu Z, Smalley KS, Sondak VK. Eroglu Z, et al. Among authors: smalley ks. Expert Rev Anticancer Ther. 2016 Jun;16(6):633-41. doi: 10.1080/14737140.2016.1178575. Epub 2016 May 12. Expert Rev Anticancer Ther. 2016. PMID: 27137746 Review.

2

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

Smalley KS, Flaherty KT. Smalley KS, et al. Br J Cancer. 2009 Feb 10;100(3):431-5. doi: 10.1038/sj.bjc.6604891. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156138 Free PMC article. Review.

3

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

Smalley KS, Sondak VK, Weber JS. Smalley KS, et al. Histol Histopathol. 2009 May;24(5):643-50. doi: 10.14670/HH-24.643. Histol Histopathol. 2009. PMID: 19283671 Review.

4

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

Smalley KS, Nathanson KL, Flaherty KT. Smalley KS, et al. Cancer Res. 2009 Apr 15;69(8):3241-4. doi: 10.1158/0008-5472.CAN-08-4305. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351826 Review.

5

Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Smalley KS. Smalley KS. J Invest Dermatol. 2010 Jan;130(1):28-37. doi: 10.1038/jid.2009.177. J Invest Dermatol. 2010. PMID: 19571822 Free article.

6

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Sondak VK, Smalley K. Sondak VK, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x. Pigment Cell Melanoma Res. 2009. PMID: 19624312 No abstract available.

7

Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.

Smalley KS, Flaherty KT. Smalley KS, et al. Future Oncol. 2009 Aug;5(6):775-8. doi: 10.2217/fon.09.56. Future Oncol. 2009. PMID: 19663727

8

PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

Smalley KS. Smalley KS. Curr Opin Investig Drugs. 2010 Jun;11(6):699-706. Curr Opin Investig Drugs. 2010. PMID: 20496265 Review.

9

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Paraiso KH, et al. Among authors: smalley ks. Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714. Br J Cancer. 2010. PMID: 20531415 Free PMC article.

10

Melanoma--an unlikely poster child for personalized cancer therapy.

Smalley KS, Sondak VK. Smalley KS, et al. N Engl J Med. 2010 Aug 26;363(9):876-8. doi: 10.1056/NEJMe1005370. N Engl J Med. 2010. PMID: 20818849 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters